Challenges of patient-facing generative artificial intelligence in hypertension care: A cross-platform evaluation of the quality, readability, and actionability of LLM-Generated patient education materials - Summary - MDSpire
Advertisement
Challenges of patient-facing generative artificial intelligence in hypertension care: A cross-platform evaluation of the quality, readability, and actionability of LLM-Generated patient education materials
To evaluate the quality, readability, and actionability of hypertension patient education materials generated by various large language models (LLMs).
Approach:
Study Design: A cross-sectional comparative study was conducted using a curated set of 20 frequently asked questions about hypertension, validated by cardiovascular experts.
Evaluation Metrics: Quality, readability, and actionability of AI-generated materials were assessed using various tools including the Patient Education Materials Assessment Tool (PEMAT-P) and seven readability formulas.
AI Platforms: Six LLM platforms were selected for analysis: ChatGPT 5.2-Thinking, DeepSeek-R1, Doubao, ERNIE Bot 4.5 Turbo, Qwen3-Max-Thinking-Preview, and Kimi K2.
Key Findings:
Many existing patient education materials exceed the recommended sixth-grade reading level, limiting patient comprehension.
Variability in output quality exists among different LLM platforms.
Interpretation:
The study highlights the need for standardized evaluation of generative AI outputs to ensure they meet patient education needs effectively.
Limitations:
The study focused on a limited number of LLM platforms.
Evaluation metrics may not capture all aspects of patient engagement and understanding.
Conclusion:
The findings suggest that while generative AI can enhance patient education materials, careful evaluation is necessary to ensure their effectiveness.
An ensemble electrocardiogram model classified derived diastolic dysfunction risk phenotypes and stratified heart failure–related death risk across external cohorts, according to findings presented at ASE 2026.